MedTrace Logo

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

NCT05134922 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-03-21

No results posted yet for this study

Summary

Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.

Conditions

  • Breast Neoplasm Malignant Female

Interventions

DRUG

Gedatolisib

Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.

Sponsors & Collaborators

  • Celcuity Inc

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134922 on ClinicalTrials.gov